Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1991 1
1992 1
1993 1
1994 2
1996 1
1998 2
1999 1
2000 3
2001 2
2002 4
2003 4
2004 1
2005 1
2006 2
2007 2
2008 3
2009 2
2010 1
2011 1
2014 1
2017 1
2019 2
2020 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Results by year

Filters applied: . Clear all
Page 1
Myeloid disorders after autoimmune disease.
Boddu PC, Zeidan AM. Boddu PC, et al. Best Pract Res Clin Haematol. 2019 Mar;32(1):74-88. doi: 10.1016/j.beha.2019.02.002. Epub 2019 Feb 7. Best Pract Res Clin Haematol. 2019. PMID: 30927978 Free PMC article. Review.
Autoimmune diseases (ADs) are associated with an increased risk not only of lymphoproliferative disorders but also of myeloid malignancies. The excess risk of myelodysplastic syndromes and/or acute myeloid leukemia is observed across seve …
Autoimmune diseases (ADs) are associated with an increased risk not only of lymphoproliferative disorders but also of myeloid maligna …
Therapy-related myeloid neoplasms: when genetics and environment collide.
McNerney ME, Godley LA, Le Beau MM. McNerney ME, et al. Nat Rev Cancer. 2017 Aug 24;17(9):513-527. doi: 10.1038/nrc.2017.60. Nat Rev Cancer. 2017. PMID: 28835720 Free PMC article. Review.
Therapy-related myeloid neoplasms (t-MN) arise as a late effect of chemotherapy and/or radiation administered for a primary condition, typically a malignant disease, solid organ transplant or autoimmune disease. ...
Therapy-related myeloid neoplasms (t-MN) arise as a late effect of chemotherapy and/or radiation administered for a primary co …
Therapy-related myeloid neoplasms after treatment for plasma-cell disorders.
Chung A, Liedtke M. Chung A, et al. Best Pract Res Clin Haematol. 2019 Mar;32(1):54-64. doi: 10.1016/j.beha.2019.02.003. Epub 2019 Feb 8. Best Pract Res Clin Haematol. 2019. PMID: 30927976 Free article. Review.
Therapy-related myeloid neoplasms (t-MN), including therapy-related acute myeloid leukaemia and myelodysplastic syndrome, are second primary malignancies (SPM) that are of growing importance as patients with plasma cell disorders (PCD) su …
Therapy-related myeloid neoplasms (t-MN), including therapy-related acute myeloid leukaemia and myelod
Genetics of therapy-related myelodysplasia and acute myeloid leukemia.
Pedersen-Bjergaard J, Andersen MK, Andersen MT, Christiansen DH. Pedersen-Bjergaard J, et al. Leukemia. 2008 Feb;22(2):240-8. doi: 10.1038/sj.leu.2405078. Epub 2008 Jan 17. Leukemia. 2008. PMID: 18200041 Review.
Myelodysplasia (MDS) and acute myeloid leukemia (AML) are heterogeneous, closely associated diseases arising de novo or following chemotherapy with alkylating agents, topoisomerase II inhibitors, or after radiotherapy. Whereas de novo MDS and AM …
Myelodysplasia (MDS) and acute myeloid leukemia (AML) are heterogeneous, closely associated diseases arising de novo or …
Clinicopathologic Features of Therapy-Related Myeloid Neoplasms in Patients with Myeloma in the Era of Novel Therapies.
Jelloul FZ, Quesada AE, Yang RK, Li S, Wang W, Xu J, Tang G, Yin CC, Fang H, El Hussein S, Khoury J, Bassett RL, Garcia-Manero G, Manasanch EE, Orlowski RZ, Qazilbash MH, Patel KP, Medeiros LJ, Lin P. Jelloul FZ, et al. Mod Pathol. 2023 Jun;36(6):100166. doi: 10.1016/j.modpat.2023.100166. Epub 2023 Mar 27. Mod Pathol. 2023. PMID: 36990279 Review.
The development of therapy-related myeloid neoplasms (t-MN) is a rare complication that can occur in myeloma patients treated primarily with novel therapies. ...Notably, 11 patients developed t-MN within 2 years. Therapy-related myelodysplastic syndrom …
The development of therapy-related myeloid neoplasms (t-MN) is a rare complication that can occur in myeloma patients treated …
Therapy-related myeloid neoplasms: pathobiology and clinical characteristics.
Sill H, Olipitz W, Zebisch A, Schulz E, Wölfler A. Sill H, et al. Br J Pharmacol. 2011 Feb;162(4):792-805. doi: 10.1111/j.1476-5381.2010.01100.x. Br J Pharmacol. 2011. PMID: 21039422 Free PMC article. Review.
Therapy-related myeloid neoplasms (t-MNs) are serious long-term consequences of cytotoxic treatments for an antecedent disorder. t-MNs are observed after ionizing radiation as well as conventional chemotherapy including alkylating agents, topoisomerase …
Therapy-related myeloid neoplasms (t-MNs) are serious long-term consequences of cytotoxic treatments for an antecedent disorde …
Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients.
Armitage JO, Carbone PP, Connors JM, Levine A, Bennett JM, Kroll S. Armitage JO, et al. J Clin Oncol. 2003 Mar 1;21(5):897-906. doi: 10.1200/JCO.2003.07.113. J Clin Oncol. 2003. PMID: 12610191 Review.
PURPOSE: Standard therapies for non-Hodgkin's lymphoma (NHL) are associated with an increased risk of developing treatment-related myelodysplastic syndrome or acute myelogenous leukemia (tMDS/AML). ...CONCLUSION: Limiting exposure to alkylating
PURPOSE: Standard therapies for non-Hodgkin's lymphoma (NHL) are associated with an increased risk of developing treatment-related
Acute myelogenous leukemia and myelodysplasia secondary to breast cancer treatment: case studies and literature review.
Cole M, Strair R. Cole M, et al. Am J Med Sci. 2010 Jan;339(1):36-40. doi: 10.1097/MAJ.0b013e3181bedb74. Am J Med Sci. 2010. PMID: 19996729 Review.
BACKGROUND AND PURPOSE: Chemotherapy and radiation therapy for breast cancer are known to increase the risk of developing a myelodysplastic syndrome (MDS) and/or acute myelogenous leukemia (AML). Alkylating agents and topoisomerase II inhibitors …
BACKGROUND AND PURPOSE: Chemotherapy and radiation therapy for breast cancer are known to increase the risk of developing a myelodysplast
Secondary myelodysplastic syndromes and leukemias.
Giles FJ, Koeffler HP. Giles FJ, et al. Curr Opin Hematol. 1994 Jul;1(4):256-60. Curr Opin Hematol. 1994. PMID: 9371291 Review.
Although therapy-related (secondary) myelodysplastic syndromes and acute nonlymphocytic leukemias are most frequently observed following therapy of Hodgkin's disease and non-Hodgkin's lymphoma, the therapy of acute lymphocytic leukemia, m …
Although therapy-related (secondary) myelodysplastic syndromes and acute nonlymphocytic leukemias are most frequ …
Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation.
Pedersen-Bjergaard J, Andersen MK, Christiansen DH. Pedersen-Bjergaard J, et al. Blood. 2000 Jun 1;95(11):3273-9. Blood. 2000. PMID: 10828005 Free article. Review.
Therapy-related myelodysplasia (t-MDS) and acute myeloid leukemia (t-AML) after high-dose chemotherapy (HD-CT) and autologous stem cell transplantation (ASCT) for malignant diseases have become an important problem. The actuarial risk has varied, but h …
Therapy-related myelodysplasia (t-MDS) and acute myeloid leukemia (t-AML) after high-dose chemotherapy (HD-CT) a …
42 results